TOP TEN perturbations for 38905_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38905_at
Selected probe(set): 225011_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38905_at (225011_at) across 6674 perturbations tested by GENEVESTIGATOR:
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-3.9822502Number of Samples:3 / 3
Experimental | oncolytic herpes simplex virus study 2 |
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
zalypsis study 2 / untreated OPM1 cell sample
Relative Expression (log2-ratio):-2.8819113Number of Samples:2 / 2
Experimental | zalypsis study 2 |
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
Control | untreated OPM1 cell sample |
OPM1 multiple myeloma cells untreated. |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)
Relative Expression (log2-ratio):-2.4459534Number of Samples:4 / 4
Experimental | dendritic cell study 6 (gardiquimod; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (CpG A; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):-2.2820063Number of Samples:4 / 8
Experimental | dendritic cell study 6 (gardiquimod; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (untreated) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
phenobarbital study 3 (10000uM) / vehicle (medium) treated hepatocyte sample
Relative Expression (log2-ratio):-2.2173977Number of Samples:2 / 2
Experimental | phenobarbital study 3 (10000uM) |
Hepatocytes treated with compound: phenobarbital (10000uM; CHEMBL40) for 24 hours. ATC code: | |
Control | vehicle (medium) treated hepatocyte sample |
Hepatocytes treated with vehicle (medium) for 24 hours. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):2.061078Number of Samples:2 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated p53HCT116 cell sample |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):-2.0593777Number of Samples:7 / 8
Experimental | dendritic cell study 6 (gardiquimod) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (untreated) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) / expO ovary cancer study 1 (adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.008873Number of Samples:2 / 4
Experimental | expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the ovary of patients with transitional cell carcinoma (NOS). | |
Control | expO ovary cancer study 1 (adenocarcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the ovary of patients with adenocarcinoma (NOS). |
expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) / expO ovary cancer study 1 (endometrioid and papillary serous adenocarcinoma; primary)
Relative Expression (log2-ratio):-1.9669666Number of Samples:2 / 4
Experimental | expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the ovary of patients with transitional cell carcinoma (NOS). | |
Control | expO ovary cancer study 1 (endometrioid and papillary serous adenocarcinoma; primary) |
Primary tumor tissue samples obtained from the ovary of patients with endometrioid and papillary serous adenocarcinoma. |
phenobarbital study 2 (10000uM) / vehicle (medium) treated hepatocyte sample
Relative Expression (log2-ratio):-1.8904219Number of Samples:2 / 2
Experimental | phenobarbital study 2 (10000uM) |
Hepatocytes treated with compound: phenobarbital (10000uM; CHEMBL40) for 8 hours. ATC code: | |
Control | vehicle (medium) treated hepatocyte sample |
Hepatocytes treated with vehicle (medium) for 8 hours. |